Relative Bioavailability Study
This is a BA study comparing the bioavailability of two new capsule formulations and one solution formulation to the isethionate capsule used in phase 1 and 2 trials in healthy volunteers.
Healthy
DRUG: PD-0332991|DRUG: PD-0332991|DRUG: PD-0332991|DRUG: PD-0332991
Plasma AUCinf for PD-0332991, 0 hour/predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post dose|Plasma Cmax for PD-0332991, 0 hour/predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post dose
Plasma AUClast for PD-0332991, 0 hour/predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post dose|Plasma Tmax for PD-0332991, 0 hour/predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post dose|Plasma t1/2 for PD-0332991, 0 hour/predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post dose|Plasma CL/F for PD-0332991, 0 hour/predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post dose|Plasma Vz/F for PD-0332991, 0 hour/predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post dose|Plasma AUClast for PF-05089326, 0 hour/predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post dose|Plasma AUCinf for PF-05089326, 0 hour/predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post dose|Plasma Cmax for PF-05089326, 0 hour/predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post dose|Plasma Tmax for PF-05089326, 0 hour/predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post dose|Plasma AUClast for PF 05089326 / PD-0332991 ratio if appropriate, 0 hour/predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post dose|Plasma AUCinf for PF 05089326 / PD-0332991 ratio if appropriate, 0 hour/predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post dose|Plasma Cmax for PF 05089326 / PD-0332991 ratio if appropriate, 0 hour/predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post dose|Plasma Tmax for PF 05089326 / PD-0332991 ratio if appropriate, 0 hour/predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post dose
This is a BA study comparing the bioavailability of two new capsule formulations and one solution formulation to the isethionate capsule used in phase 1 and 2 trials in healthy volunteers.